ADAMTS13 and thrombotic thrombocytopenic purpura: Caplacizumab (ALX-0081) was recently approved by the FDA to treat thrombotic thrombocytopenic purpura (TTP), a disease characterized by the presence of active ultra-large VWF multimers due to insufficient ADAMTS13 activity48.